# A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period

> **NCT06524375** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Genentech, Inc.** · enrollment: 118 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** cBTKi Monotherapy

## Key facts

- **NCT ID:** NCT06524375
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-09
- **Primary completion:** 2026-10-31
- **Final completion:** 2030-01-31
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06524375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06524375, "A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06524375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*